NJ Bio Bridges the Translation Research Gap with the Asset Purchase and Integration of L2P® Services
NJ Bio, Inc. now offers translational research services after completing asset purchase and full integration of the services of L2P® Research Labs, enhancing the discovery-to-development pipeline
L2P Research Labs® was well-recognized for its integrated pre-clinical R&D support, particularly in oncology research and for services supporting IND applications. With the integration of these services into NJ Bio’s offerings, L2P Research Labs®, has ceased independent operations and its portfolio of preclinical and translational research services will now be offered exclusively under NJ Bio.
NJ Bio will now be able to offer preclinical oncology and translational research capabilities such as syngeneic, PDX, orthotopic, and humanized mouse models, along with ILD models, and advanced in vivo imaging. All services are conducted under GLP-aligned practices, with NJ Bio pursuing AAALAC accreditation and OLAW assurance to further strengthen its compliance and quality standards.
About NJ Bio
NJ Bio, Inc. is a leading contract research organization headquartered in Princeton, NJ, with additional chemistry facilities in Bristol, PA and Mumbai, India, providing integrated chemistry and biology services to companies in the biotech and pharmaceutical sectors. The NJ Bio team has robust expertise in bioconjugation, synthetic organic chemistry, protein-based biopharmaceuticals, translational research and GMP manufacturing that enables clients to receive customized solutions that could speed up their drug discovery and development programs. To learn more about our services, visit www.njbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251106703527/en/
Website: https://njbio.com/
Contact
NJ Bio, Inc.
Rachel Fernandes
info@njbio.com
This news is a press release provided by NJ Bio, Inc..
